Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 17

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alogliptin
  • Sponsor:Tecnimede-Sociedade Tecnico-Medicinal S.A.

Carcinoid syndrome

Not yet recruiting

Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Gastrointestinal neuroendocrine tumour

Not yet recruiting

Study of Lutetium-177 and Yttrium-90 DOTATATE combination therapy for patients with inoperable gastrointestinal neuroendocrine tumors

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dotatate
  • Sponsor:Narodowe Centrum Badan Jadrowych

Diabetic neuropathy+1

Not yet recruiting

Efficacy and Safety of OXT-328 5% Topical Gel for Symptom Relief in Patients with Chemotherapy‑Induced, Diabetic, and Cervical Radiculopathy Peripheral Neuropathy

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years

Adrenoleukodystrophy

Not yet recruiting

Safety and Early Benefit of Allogeneic Bone Marrow‑Derived Mesenchymal Stromal Cells in Children and Adolescents with X‑Linked Adrenoleukodystrophy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Sponsor:Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus

Type 2 diabetes mellitus

Not yet recruiting

Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Albiglutide
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus+4

Not yet recruiting

Effect of semaglutide on weight loss and metabolic control in liver transplant candidates with obesity

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Hypogonadism

Not yet recruiting

Effect of Semaglutide and Testosterone Undecanoate on Body Composition in Obese Men with Functional Hypogonadism: A Randomized 52‑Week Trial

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Rigshospitalet

Monogenic diabetes

Not yet recruiting

Effect of semaglutide added to sulfonylurea on blood sugar in adults with HNF1A‑MODY and HNF4A‑MODY

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Steno Diabetes Center Copenhagen

Adrenocortical carcinoma

Not yet recruiting

Cisplatin with drug combination in hyperthermic intraperitoneal chemotherapy for stage II‑III adrenocortical carcinoma patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Neuroendocrine carcinoma

Not yet recruiting

Phase II Study of BI 764532 Added to Platinum Chemotherapy in Adults with Advanced Large‑Cell Neuroendocrine Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Igg-Like T Cell Engager Binding To Dll3 And Cd3
  • Sponsor:Technische Universitat Dresden

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.